• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
10 results

Pharmacyclics LLC v. Acerta Pharma B.V. et al

Docket 1:17-cv-01582, Delaware District Court (Nov. 3, 2017)
Judge Richard G. Andrews, presiding, Judge Sherry R. Fallon
Patent
DivisionWilmington
FlagsCLOSED, DISCOVERY-SRF, MEDIATION-CJB, PATENT, VACANTJUDGESHIP-2017
Cause35:271 Patent Infringement
Case Type830 Patent
Tags830 Patent, 830 Patent
Patent9079908; 9139591; 9556182, 9079908, 9139591, 9556182
Plaintiff Pharmacyclics LLC
Defendant Acerta Pharma B.V.
Defendant Acerta Pharma LLC
...
cite Cite Docket
Analyze

No. 173 MEMORANDUM ORDER: Providing claim construction for multiple terms in U.S. Patent Nos. 9,079,908, ...

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 173 (D.Del. Aug. 7, 2019)
[This is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application."
"heteroalkyl" a. Plaintiff's Proposed Construction: "Optionally substituted alkyl radicals in which one or more skeletal chain atoms is a heteroatom, e.g., oxygen, nitrogen, sulfur, silicon, phosphorus or combinations thereof.
c. Court's Construction : "Optionally substituted alkyl radicals in which one or more skeletal chain atoms is a heteroatom, e.g., oxygen, nitrogen, sulfur, silicon, phosphorus or combinations thereof.
Plaintiff argues that, consistent with Anderson, it would have been redundant for the asserted patents to explicitly state that the number of carbon atoms is bounded by some reasonable limit.
Not only is the specification "the single best guide" for claim construction, Phillips, 415 F.3d at 1315, but the patentee has "acted as his own lexicographer and clearly set forth a definition of the disputed term," CCS Fitness, Inc. v. Brunswick Corp., 288 F.3d 1359, 1366 (Fed. Cir. 2002).
cite Cite Document
Analyze

No. 178 STIPULATION of Dismissal with Prejudice, by AstraZeneca Pharmaceuticals LP

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 178 (D.Del. Oct. 22, 2019)
Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), Plaintiff Pharmacyclics LLC and Defendants Acerta Pharma B.V., Acerta Pharma LLC, and AstraZeneca Pharmaceuticals LP, hereby stipulate that the above-captioned action, including but not limited to all claims and counterclaims asserted therein, be dismissed with prejudice, each party agreeing to bear its own fees and costs.
cite Cite Document
Analyze

No. 140 Joint Claim Construction Brief, filed by Pharmacyclics LLC

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 140 (D.Del. Apr. 22, 2019)
Log in to see more
cite Cite Document
Analyze

No. 134

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 134 (D.Del. Apr. 1, 2019)

cite Cite Document
Analyze

No. 23

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 23 (D.Del. Jan. 30, 2018)

cite Cite Document
Analyze

No. 12

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 12 (D.Del. Jan. 9, 2018)

cite Cite Document
Analyze

No. 1

Document Pharmacyclics LLC v. Acerta Pharma B.V. et al, 1:17-cv-01582, No. 1 (D.Del. Nov. 3, 2017)

cite Cite Document
Analyze
1 2 >>